Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
about
Anti-vascular endothelial growth factor for diabetic macular oedemaAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaVascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAnti-angiogenic therapies for metastatic colorectal cancerAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAnti-angiogenic therapy for metastatic colorectal cancerGPR56 Regulates VEGF production and angiogenesis during melanoma progressionEMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGFRadioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activityCancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticleRequirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interferenceTumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancerProtocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumorsThe vascular endothelial growth factor (VEGF) family: angiogenic factors in health and diseaseAngiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer CellsCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewTargeted drugs and Psycho-oncological intervention for breast cancer patientsPemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures ReviewAntiangiogenic mechanisms and factors in breast cancer treatmentNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialDrug discovery in ophthalmology: past success, present challenges, and future opportunitiesProfile of bevacizumab and its potential in the treatment of cervical cancerProfile of nintedanib in the treatment of solid tumors: the evidence to dateMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Chloroquine and hydroxychloroquine for cancer therapyExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesComparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationSystemic and targeted therapies for early-stage lung cancerWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesTyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatmentMolecular therapy of colorectal cancer: progress and future directionsMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaPathogenesis of herpes stromal keratitis--a focus on corneal neovascularization
P2860
Q24193083-ED604D0D-A254-49F5-8149-7E4B8F6373C5Q24202071-083E959A-AA33-422D-AFA0-C0530319F3C5Q24202199-0AAF80CF-BA5E-416D-B90C-D879255A3FC0Q24240165-A8180054-5EC6-40DF-8B41-2F252E2E22DAQ24241813-6D56A952-8321-4578-8BC7-9D88FDDE0C6DQ24242242-DA7D63FE-4D58-4211-9712-2C5E6366C29AQ24243297-6E395CE3-6F60-460A-BE61-FA0D3BE6D8B0Q24309605-966777EF-A50B-4988-84DE-5053D0F8D920Q24310236-DB1AEE63-9E82-48CD-8F05-3B2278BD030CQ24313293-29386AD6-0135-4C1C-8716-53F63837EBABQ24546366-00EE4E76-B970-4174-ADD2-99A89B57F28EQ24560011-68A6D477-F878-4404-B6BE-70102738038EQ24563464-EAD5F5A1-3E8A-43FA-BF1E-1E42807F4E31Q24652733-2AAD5BCE-53AF-4FD5-9A06-5F184BFF265BQ24658529-6B9D52A0-3E9C-4C9B-9233-22968486E94FQ24678647-2D4B44D4-FB88-486E-9912-D65DB12A1CD5Q24796165-AFD01CBB-5E22-44D5-9FD4-28FF76659441Q24804828-FE0DF109-18EE-47D3-A7BC-0F6F2CE715DBQ26738643-457DA004-E6A0-406C-A0A8-A23B9338A3B2Q26740067-16CFE044-B170-4587-A166-65897EF97350Q26748919-2606A22D-A3B5-406C-BC86-90A7EA0D610CQ26750670-A22A39F3-1CA6-47DE-9913-60D02F1D42C1Q26751226-BB011093-0448-4167-A5DD-08A81653417DQ26769884-2A7FB923-5558-45A7-BCD8-E6157F565983Q26771638-ED198EB3-0FFB-446F-84CD-E9F86251C580Q26774168-15CCFA7E-DCEA-4C87-BDC4-36527E4CBD13Q26775134-4340B69A-C90C-4CF0-BDCF-17A04E3CDEBFQ26822717-1D87988F-A50C-4E1E-8C6F-193859515DC7Q26823757-EA39313D-8C75-401C-948F-BE5C648E0B47Q26827797-9DB17208-60A4-4CBD-AB2F-5244E4DCA647Q26828930-86042ED6-5C89-44B9-A707-88A4805575DBQ26852289-45999ECA-70F7-44BC-BBF5-8162D074F3CFQ26865490-A487E22D-5732-45E5-8796-32C3E233E600Q26991991-6CFE9EA6-F7F2-405E-A4ED-35A7C6F6A1A6Q26993238-50BC6F0B-6712-4245-8B35-A0539A6691F8Q26995399-C7506300-AB38-41B5-A05A-EF358739C20EQ26998914-9759D1CC-32A9-48E0-93A8-549A05ABBBA9Q27005764-912A9C53-B126-440E-99B7-ABA6AE5B3C89Q27021470-604F05DA-0A9E-4D24-A895-E8A2BD5F633BQ27023951-E79D56A0-1FAD-4D73-B38A-69DF6011E435
P2860
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@ast
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@en
type
label
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@ast
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@en
prefLabel
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@ast
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@en
P2093
P3181
P356
P1476
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
@en
P2093
P2888
P304
P3181
P356
10.1038/NRD1381
P407
P577
2004-05-01T00:00:00Z
P5875
P6179
1006489607